Difference between revisions of "Abiraterone"
Jump to navigation
Jump to search
| Line 10: | Line 10: | ||
[[Category:Genitourinary pathology]] | [[Category:Genitourinary pathology]] | ||
[[Category:Clinical]] | [[Category:Clinical]] | ||
[[Category:Drugs]] | |||
Revision as of 14:50, 30 May 2016
Abiraterone is an androgen synthesis inhibitor used to treat prostate cancer.[1]
See also
References
- ↑ Mitsiades, N. (Aug 2013). "A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.". Cancer Res 73 (15): 4599-605. doi:10.1158/0008-5472.CAN-12-4414. PMID 23887973.